Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804058 | 0.85 | EPHX2 (0.44) | EPHX2TRPM5KCNH2SCN5ASCN9A | |
| SCHEMBL15350290 | 0.80 | MRGPRX4 (0.47) | L3MBTL1EPHX2DPP4HCAR2NAPRT | |
| SCHEMBL2714328 | 0.77 | TSHR (0.51) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL979202 | 0.76 | ALDH1A1 (0.41) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL30168643 | 0.76 | DPP4 (0.38) | L3MBTL1DPP4PREPFAPDPP8 | |
| SCHEMBL24214200 | 0.75 | L3MBTL1 (0.42) | L3MBTL1EPHX2HCAR2KCNH2SCN5A | |
| SCHEMBL31049011 | 0.75 | DPP4 (0.39) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL796475 | 0.75 | L3MBTL1 (0.72) | L3MBTL1EPHX2KCNH2SCN5ASCN9A | |
| SCHEMBL15350077 | 0.74 | L3MBTL1 (0.41) | L3MBTL1EPHX2HCAR2KCNH2SCN5A | |
| SCHEMBL978676 | 0.73 | CA12 (0.52) | HCAR2NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | L3MBTL1 2928/4885EPHX2 182/4885DPP4 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.